High-yield points
- Children's CCMs hemorrhage at about 2–3% per year overall, but about 11% per year after a bleed, clustered in the first 3 years .
- Highest-risk features: prior hemorrhage, brainstem location and an associated DVA .
- Hereditary forms:
- Genetics: autosomal dominant KRIT1, CCM2 or PDCD10; KRIT1 Q455X is a Hispanic founder variant .
- PDCD10 is the most aggressive genotype .
- Familial children bleed at about 5% per year .
- The three indications:
1. symptomatic hemorrhage (especially recurrent, or pial-reaching brainstem lesions); 2. epilepsy (85.7% Engel I after resection; LITT is an option); 3. growth or mass effect, including radiation-induced lesions .
- Incidental and asymptomatic deep lesions: observe.
- Prior radiation: expect de novo CCMs .
Landmark papers
- Natural history in children (Gross et al., J Neurosurg Pediatr 2016): a single-center untreated cohort of 167 children (222 CCMs). The overall annual hemorrhage rate was 3.3% .
- Treat_CCM (Lanfranconi et al., Lancet Neurol 2023): propranolol in 83 adults with symptomatic familial CCM. Symptomatic hemorrhage or new deficit occurred at 1.7 vs 3.9 per 100 person-years (HR 0.43), a signal of efficacy in a phase 2 pilot, not proof .
Cerebral cavernous malformations (CCMs, cavernomas) are clusters of thin-walled, endothelial-lined caverns with no intervening brain, ringed by hemosiderin.
- Angiography: they are angiographically occult.
- Imaging: they are best seen on susceptibility-weighted imaging (SWI).
- In children:
- Presentation: hemorrhage or seizures.
- Familial forms (family history in about 10% of children ) bring multiple, new and growing lesions over a lifetime.
- The key management questions:
- Is the child having symptomatic hemorrhage, epilepsy, or growth or mass effect?
- Can the lesion be removed safely?
Natural history in children
- Single-center untreated cohort (167 children, 222 CCMs) :
- Presentation:
- hemorrhage, 62%;
- seizures, 35%;
- incidental, 26%.
- Associations: family history in 10%, multiple lesions in 15%, and a visible developmental venous anomaly (DVA) in 20%.
- Annual hemorrhage rate (overall 3.3%):
- 0.5% for incidental lesions;
- 11.3% after a hemorrhage, rising to 18.2% in the first 3 years (temporal clustering).
- Predictors of hemorrhage:
- prior hemorrhage (HR 4.6);
- brainstem location (HR 4.4);
- associated DVA (HR 2.9).
- Permanent morbidity per hemorrhage: 29% overall.
- Brainstem, thalamic or basal ganglia lesions: 45%.
- Lobar or cerebellar lesions: 15%.
- Five-year cohort (129 children) :
- Cumulative 5-year (re)bleeding risk: 15.9% overall, 30.2% after presenting with hemorrhage, and 29.5% for brainstem CCMs.
- Who presented with bleeding: brainstem location and family history predicted hemorrhage at presentation.
- Largest pediatric cohort (257 children, 786 brain and 14 spinal lesions) :
- Annual hemorrhage risk: 1.9%.
- Higher risk with:
- sporadic or post-radiation type;
- brainstem or spinal location;
- extracapsular hemorrhage, larger volume, or an associated DVA.
- Molecular findings:
- PIK3CA somatic variants were found in 62% of operated lesions and in 96% of DVA-associated CCMs, and were linked to aggressiveness.
- MAP3K3 variants lowered hemorrhagic risk.
Hereditary forms
- Familial CCM (FCCM) :
- Genetics: autosomal dominant, from germline variants in KRIT1 (CCM1), CCM2 or PDCD10 (CCM3).
- Lesions: multiple, typically 6–20, sometimes hundreds. They increase in number over time, and individual lesions grow or shrink.
- Course: up to 50% of carriers stay asymptomatic.
- Outside the brain:
- cutaneous vascular lesions in 9%;
- retinal lesions in almost 5%;
- spinal cord lesions occur.
- Diagnosis of FCCM :
- multiple CCMs;
- or a single CCM plus an affected relative;
- or a pathogenic variant.
- KRIT1 "Common Hispanic Mutation": a founder Q455X variant in Hispanic families of Mexican descent .
- PDCD10 (CCM3): the most aggressive genotype :
- greater lesion burden;
- more hemorrhages earlier in life;
- other features: scoliosis, cognitive disability and skin lesions.
- Children with FCCM (41 children, multicenter) :
- Annual symptomatic hemorrhage rate: 5.0%.
- Cumulative risk: 7.3% at 1 year, 14.6% at 2 years and 17.1% at 5 years.
- Higher (33.3%) with prior hemorrhage or a CCM2 genotype.
- Number of brainstem and posterior fossa lesions predicted future bleeding.
- Radiation-induced (de novo) CCMs after cranial irradiation :
- Pediatric surgical series (7 patients): detected a mean 5.8 years after radiation.
- Who was operated on: most were symptomatic (71%); the rest had asymptomatic growth or hemorrhage (29%).
- Outcome: gross total resection in all, with no later hemorrhage.
- Practical genetics (Angioma Alliance and GeneReviews) :
- Who to test: offer genetic testing and counseling for multiple lesions or a family history.
- Relatives: test at-risk relatives if the familial variant is known.
- Imaging: use MRI with SWI for new symptoms.
Indications for treatment
Treat when one of the following is present.
- Symptomatic hemorrhage:
- Accessible lesions: hemorrhage with a deficit, especially a second hemorrhage, favors resection. The risk clusters in the years after a bleed .
- Brainstem lesions (48 children) :
- Who was operated on: surgery was chosen for lesions that had bled (91%), reached a pial surface (73%) and were larger (1.0–3.1 vs. 0.5–1.6 cm).
- Outcome after gross total resection: all improved or were stable.
- Overall: mRS change was similar between surgical and conservative groups.
- Epilepsy (systematic review plus series, 223 children) :
- Seizure freedom after resection: Engel I in 85.7%.
- Deficits: expected in 3.7% and unexpected in 2.8%.
- Prognosis: longer epilepsy duration and drug resistance trended toward worse outcomes, which argues for earlier surgery.
- Technique: resect the hemosiderin-stained rim for epilepsy (see caveats).
- Laser ablation (LITT): in 19 mostly adult patients with epileptogenic CCMs (most with chronic refractory epilepsy), 82% were Engel I, with no hemorrhage .
- Growth or mass effect:
- Enlarging lesions with new symptoms, and symptomatic radiation-induced lesions, are resected .
- Cortical lesion surgery: low risk (0.9% surgical risk) .
- Usually observe:
- incidental lesions (0.5% per year) ;
- asymptomatic deep lesions;
- most of the many lesions in familial disease. Treat only the symptomatic one .
Medical therapy and precautions
- Propranolol (Treat_CCM, 83 adults with symptomatic familial CCM) :
- Result: symptomatic hemorrhage or new deficit at 1.7 vs. 3.9 per 100 person-years (HR 0.43).
- Status: a signal of efficacy in a phase 2 pilot, not proof.
- Precautions in FCCM (GeneReviews) :
- Use with caution: NSAIDs, anticoagulants and thrombolytics. If anticoagulation is essential for life-threatening thrombosis, it can still be given, with careful dosing and monitoring.
- Avoid CNS radiation when possible, because it can create new lesions.
- Radiosurgery: a consideration for deep lesions in adults, but radiation-induced CCMs make it unattractive in children (see caveats).
Related topics
- LITT in Epilepsy Surgery: laser ablation of epileptogenic lesions.
- Epilepsy Surgery in Children: Overview: surgical work-up for lesional epilepsy.
- Brain AVMs in Children: another hemorrhagic vascular malformation.
- Brainstem Cavernous Malformations in Children: brainstem lesions in depth.
References
- Gross BA, Du R, Orbach DB, et al. The natural history of cerebral cavernous malformations in children. J Neurosurg Pediatr 2016;17(2):123–128. doi:10.3171/2015.2.PEDS14541. PMID 26474098. verified
- Santos AN, Rauschenbach L, Saban D, et al. Natural course of cerebral cavernous malformations in children: a five-year follow-up study. Stroke 2022;53(3):817–824. doi:10.1161/STROKEAHA.121.035338. PMID 34706565. verified
- Benichi S, Balducci E, Benzakoun J, et al. Clinical and molecular landscape of paediatric cerebral and spinal cavernous malformations. Brain Commun 2025;7(6):fcaf408. doi:10.1093/braincomms/fcaf408. PMID 41216139. verified
- Flemming KD, Smith E, Marchuk D, Derry WB. Familial cerebral cavernous malformations. In: Adam MP, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993–; updated 2023. PMID 20301470. verified
- Choquet H, Nelson J, Pawlikowska L, et al. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis 2014;37(1):57–63. doi:10.1159/000356839. PMID 24401931. verified
- Shenkar R, Shi C, Rebeiz T, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med 2015;17(3):188–196. doi:10.1038/gim.2014.97. PMID 25122144. verified
- Geraldo AF, Alves CAPF, Luis A, et al. Natural history of familial cerebral cavernous malformation syndrome in children: a multicenter cohort study. Neuroradiology 2023;65(2):401–414. doi:10.1007/s00234-022-03056-y. PMID 36198887. verified
- Keusch DS, Choi JH, Lopes C, et al. Operative management of pediatric radiation-induced cavernous malformations: insights from a single-center cohort. Childs Nerv Syst 2026;42(1). doi:10.1007/s00381-026-07359-w. PMID 42362942. verified
- Akers A, Al-Shahi Salman R, Awad IA, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665–680. doi:10.1093/neuros/nyx091. PMID 28387823. verified
- Choi JH, Albanese J, Riordan CP, et al. Management strategies and long-term outcomes of pediatric brainstem cavernous malformations: conservative management vs surgery. Neurosurgery 2026 (online ahead of print). doi:10.1227/neu.0000000000004042. PMID 41996091. verified
- Bosisio L, Cognolato E, Nobile G, et al. Surgical treatment of cavernous malformation-related epilepsy in children: case series, systematic review, and meta-analysis. Neurosurg Rev 2024;47(1):251. doi:10.1007/s10143-024-02491-0. PMID 38819574. verified
- Willie JT, Malcolm JG, Stern MA, et al. Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations. Epilepsia 2019;60(2):220–232. doi:10.1111/epi.14634. PMID 30653657. verified
- Lanfranconi S, Scola E, Meessen JMTA, et al. Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol 2023;22(1):35–44. doi:10.1016/S1474-4422(22)00409-400409-4). PMID 36403580. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
- Reference 4 (GeneReviews) was checked against its PubMed/Europe PMC summary (update 2023-07-27); the full chapter could not be retrieved.
- References 8 and 10 are 2026 online-first; 8 lacks pages.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- offering genetic testing for multiple lesions (the GeneReviews summary supports testing at-risk relatives);
- resecting the hemosiderin rim for epilepsy;
- the reluctance to use radiosurgery in children;
- the "second hemorrhage" threshold for deep lesions.
- The Angioma Alliance recommendations (9) are summarized only at the level of the abstract and the GeneReviews summary.
- Treat_CCM enrolled adults.
- The Hispanic founder variant is identified in reference 5; "Mexican descent" is standard teaching.
- The figure is an original schematic.